Canceromatosis modelling of intraperitoneal implantation of solid tumours in mice or human


In the work there are described the parameters of a canceromatosis by the intraperitoneal implantation of the solid tumors: Lewis lung carcinoma (LLC) to syngeneic regular males of C57Bl6j mice and human subcutaneous breast cancer (BC) xenografts BC-1 to immunodeficient females of mice Balb/c nude. There was shown aggressive LLC canceromatosis which was realized as the solid tumor nodule (from 30-40 singles to the total) growths on a peritoneum (parietal or visceral) and a mesenteries or of the intestinal lymphoid nodules, development of space-occupying ascites (to 3.0 ml), and death of mice for 12-14 days. This model is characterized as moderately sensitive to paclitaxel (inhibition of tumor growth by 84% and increasing of life span of mice up to 46%). BC-1 canceromatosis was low aggressive with development of the single (solitary) solid tumor nodule on a peritoneum in the place of implantation and reaching within 3 weeks of average volume to 300 mm3 without accumulation of ascites, decreasing of the life span or death of mice. This model is characterized as moderately sensitive to paclitaxel with inhibition of the tumor growth by 85%. The obtained data give the ground to consider that both intraperitoneal solid tumors represent themselves to be sensitive to systemic chemotherapy for the model of canceromatosis differing in various aggressiveness of a course and specific symptomatics of the process. For an aggressive LLC canceromatosis the evidential base of efficiency has to be formed on the basis of inhibition of growth of the peritoneal tumor nodules in peritoneal cavity and accumulation ofperitoneal ascites, and also the increase of the mice life span, for a nonaggressive BC-1 canceromatosis - inhibition of the growth of the peritoneal tumor nodule.

Full Text

Restricted Access

About the authors

N. V Andronova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

G. B Smirnova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

Ju. A Borisova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

M. S Kalish'yan

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

Elena M. Treshchalina

N.N. Blokhin Russian Cancer Research Center

MD, PhD, DSc, Prof., Head of the Laboratory combination therapy of tumors of the Research Institute of Experimental Diagnostics and Therapy of Tumors Moscow, 115478, Russian Federation


  1. Kodera Y., Nakanishi H., Yamamura Y., Shimizu Y. Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. Int. J. Cancer Predict. Oncol. 1998; 79: 429-33.
  2. Чистяков С.С., Одишелидзе Н.В., Габуния З.Р. Значение диагностики субклинической интраперитонеальной диссеминации у больных раком желудка. Рос. мед. журн. Приложение «Онкология». 2011; (2): 49.
  3. Давыдов М.И., Тер-Ованесов М.Д., Абдихакимов А.Н., Марчук В.А. и др. Рак желудка: предоперационное обследование и актуальные вопросы стадирования. Практическая онкология. 2001; 7 (3): 9-17.
  4. Давыдов М.И., Тер-Ованесов М.Д., Буйденок Ю.В., Полоцкий Б.Е., Горбунова В.А., Абдуллаев А.Г. Гипертермическая интраоперационная интраперитонеальная химиотерапия при раке желудка: существует ли реальная возможность изменить прогноз? Вестник РОНЦ им. Н.Н. Блохина РАМН. 2010; 21 (1): 11-20.
  5. Давыдов М.И., Поддубный Б.К., Абдихакимов А.Н., Губин А.Н., Тер-Ованесов М.Д., Марчук В.А., Берая В.В. Роль лапароскопии в комплексном обследовании больных с распространенными формами рака желудка. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2002; 3 (13): 25-30.
  6. Трещалина Е.М. Иммунодефицитные мыши разведения РОНЦ им. Н.Н. Блохина РАМН. Возможности использования. М.: Изд. Группа РОНЦ; 2010.
  7. Teicher B.A., Andrews P.A. Anticancer Drug Development Guide. Preclinical Screening, Clinical Trials, and Approval. 2-nd Ed. Totowa; New Jersey: Humana Press; 2004.
  8. Трещалина Е.М., Жукова О.С., Герасимова Г.К., Андронова Н.В., Гарин А.М. Методические рекомендации по доклиническому изучению противоопухолевой активности лекарственных средств. В кн.: Руководство по проведению доклинических исследований лекарственных средств. М.: Гриф и К; 2012: 642-57.
  9. Furusawa E., Chou S.C., Hirazumi A., Melera A. Antitumour potential of Pollen extract on Lewis lung carcinoma implanted intraperitoneally in syngeneic mice. Cancer Lett. 1992; 50: 71-8.
  10. Hirazumi А., Furusawa E., Chou S.C., Hokama Y. Anticancer activity of morinda citrifolia (Noni) on intraperitoneally implanted lewis lung carcinoma in syngeneic mice. Proc. West. Pharmacol. Soc. 1994; 37: 145-6.
  11. Wang M.Y., West B.J., Jensen C.J., Nowicki D., Chen S.U., Palu A.K., Anderson G. Morinda citrifolia (Noni): A literature review and recent advanced in Noni research. Acta Pharmacol. Sin. 2002; 23 (12): 1127-41.
  12. Трещалина Е.М. Коллекция опухолевых штаммов человека. М.: Практическая медицина; 2009.



Abstract: 133

Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2016 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies